Please assess the completion status of the following clinical trial:

Trial Title: Combination Bortezomib and Rituximab in Patients With Waldenstrom's Macroglobulinemia (WM)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older~* Patients with previously untreated WM and those who have received prior therapy are eligible~* Must have received prior therapy for their WM and have relapsed or refractory WM.~* CD20 positive disease based on any previous bone marrow immuno-histochemistry or flow cytometric analysis performed up to 3 months prior to enrollment.~* Measurable disease~* ECOG Performance Status 0,1, or 2~* Total bilirubin \< 2.0 mg/dl~* AST \< 3 x ULN~* Life expectancy of greater than 12 weeks~Exclusion Criteria:~* Uncontrolled infection~* Other active malignancies~* Cytotoxic chemotherapy less than 3 weeks, or biologic therapy less than 2 weeks, or corticosteroids less than 2 weeks, prior to registration.~* Other concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy considered investigational~* Known to be HIV positive or HEP B positive~* Radiation therapy less than 2 weeks prior to registration~* Grade 2 or greater peripheral neuropathy~* Myocardial infarction within 6 months rior to enrollment or has NYHA Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities.~* Hypersensitivity to bortezomib, boron, or mannitol~* Pregnant or breast feeding women~* Other investigational drugs within 14 days of enrollment~* Serious medical or psychiatric illness likely to interfere with participation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- bortezomib and rituximab (Type: EXPERIMENTAL): bortezomib and rituximab

Based on this trial design, predict the completion outcome and termination type (if applicable).